AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel, is conducting a clinical study titled A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR). The study aims to assess the safety and efficacy of new treatment combinations for colorectal cancer, focusing on patients with Mismatch-repair-proficient (pMMR) and Microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
The study is testing two treatment regimens: an experimental group receiving Volrustomig combined with FOLFIRI and Bevacizumab, and a comparator group receiving only FOLFIRI and Bevacizumab. These interventions are intended to improve treatment outcomes for patients who have not previously received systemic treatment for advanced or metastatic disease.
This Phase II study is designed as an open-label, randomized, parallel assignment with no masking, primarily for treatment purposes. Participants are allocated to different treatment arms to compare the efficacy of the interventions.
The study began on March 12, 2025, with the last update submitted on July 1, 2025. These dates are crucial as they mark the progress and current status of the study, which is still in the recruiting phase.
This update could influence AstraZeneca’s stock performance positively, as successful outcomes may enhance their market position in oncology. Investor sentiment might be buoyed by the potential for new, effective treatments in a competitive industry landscape.
The study is ongoing, and further details are available on the ClinicalTrials portal.